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Abstract
Acetyl Coenzyme A-dependent N-, O- and N,O-acetylation of aromatic amines and hydrazines by arylamine N-
acetyltransferases is well characterised. Here, we describe experiments demonstrating that human arylamine N-
acetyltransferase Type 1 and its murine homologue (Type 2) can also catalyse the direct hydrolysis of acetyl Coenzyme
A in the presence of folate. This folate-dependent activity is exclusive to these two isoforms; no acetyl Coenzyme A
hydrolysis was found when murine arylamine N-acetyltransferase Type 1 or recombinant bacterial arylamine N-
acetyltransferases were incubated with folate. Proton nuclear magnetic resonance spectroscopy allowed chemical
modifications occurring during the catalytic reaction to be analysed in real time, revealing that the disappearance of acetyl
CH3 from acetyl Coenzyme A occurred concomitantly with the appearance of a CH3 peak corresponding to that of free
acetate and suggesting that folate is not acetylated during the reaction. We propose that folate is a cofactor for this reaction
and suggest it as an endogenous function of this widespread enzyme. Furthermore, in silico docking of folate within the
active site of human arylamine N-acetyltransferase Type 1 suggests that folate may bind at the enzyme’s active site, and
facilitate acetyl Coenzyme A hydrolysis. The evidence presented in this paper adds to our growing understanding of the
endogenous roles of human arylamine N-acetyltransferase Type 1 and its mouse homologue and expands the catalytic
repertoire of these enzymes, demonstrating that they are by no means just xenobiotic metabolising enzymes but probably
also play an important role in cellular metabolism. These data, together with the characterisation of a naphthoquinone
inhibitor of folate-dependent acetyl Coenzyme A hydrolysis by human arylamine N-acetyltransferase Type 1/murine
arylamine N-acetyltransferase Type 2, open up a range of future avenues of exploration, both for elucidating the
developmental role of these enzymes and for improving chemotherapeutic approaches to pathological conditions
including estrogen receptor-positive breast cancer.
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Introduction
Arylamine N-acetyltransferases (NATs) are well characterised
xenobiotic-metabolising enzymes which catalyse the acetyl Coen-
zyme A (AcCoA)-dependent N-, O- and N,O-acetylation of
aromatic amines and hydrazines. They have also been shown to
play important endogenous roles as well as having potential as
novel targets for pharmacological intervention [1,2].
The human genome contains two adjacent NAT genes and a
pseudogene (NATP). Both functional genes encode enzymes which
catalyse the transfer of an acetyl group from AcCoA to an
arylamine resulting in the formation of an amide bond, although
their individual substrate specificities differ [2,3]. One of these
enzymes, arylamine N-acetyltransferase Type 2 ((HUMAN)-
NAT2), is responsible for the acetylation of a range of drugs and
xenobiotics and came to prominence because of its role in the
polymorphic metabolism of the anti-tubercular agent isoniazid.
Specific combinations of single nucleotide polymorphisms (SNPs)
in the (HUMAN)NAT2 gene are associated with slow acetylation of
a number of therapeutic agents as well as industrial chemicals such
as arylamines.
The second functional human NAT gene encodes human
arylamine N-acetyltransferase Type 1 ((HUMAN)NAT1) and has
also been shown to be polymorphic, although the consequences of
the individual SNPs at this locus have been called into question
because many of them are outside the coding region [4]. The
substrate specificity of (HUMAN)NAT1 differs from that of
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(HUMAN)NAT2 in that its preferred model substrate is the
arylamine para-aminobenzoic acid (pABA) rather than the
arylhydrazine compounds preferred by (HUMAN)NAT2.
Determination of the crystal structures of (HUMAN)NAT1 and
(HUMAN)NAT2 has allowed their substrate specificities to be
explained. These studies have shown that the catalytic triad of
Cys69, His107 and Asp122 initially identified in the prokaryotic
NAT of Salmonella typhimurium ((SALTY)NAT) [5] has the same
orientation in both human NAT enzymes in which Cys is located
at position 68 and His at 106 [6]. The architecture of the active
sites of (HUMAN)NAT1 and (HUMAN)NAT2 reinforced earlier
evidence identifying the importance of residues 125–129 in
determining substrate specificity [7] and substantiated the
importance of the C-terminus in controlling activity, as originally
demonstrated by Sinclair and Sim [8]. These observations help to
explain why, whilst (HUMAN)NAT1 metabolises a spectrum of
substrates which overlaps that of (HUMAN)NAT2, its specificity
profile is unique.
While (HUMAN)NAT1 is structurally similar to (HUMAN)-
NAT2, it is biologically distinct in that it is expressed during
embryonic development (as early as the four-cell stage), in placenta
during trimester one and throughout pregnancy [9–11], and in
stem cells. The enzymatic profile of NAT1 expression in different
human foetal organs [12] illustrates its widespread tissue
distribution, which differs from the much more restricted
distribution of (HUMAN)NAT2, and many strands of evidence
suggest a link between (HUMAN)NAT1 and folate [13–15].
The potential role of (HUMAN)NAT1 in folate clearance in the
embryo and placenta is of particular interest because of the fact
that folic acid supplementation is effective in the prevention of
neural tube defects (NTDs) [16]. Rare loss-of-function mutations
in (HUMAN)NAT1 are associated with reduced risk of spina bifida,
and (HUMAN)NAT1 genotype has therefore been identified as a
risk factor for this condition [17]. The chromosomal region
marked by (HUMAN)NAT1 and (HUMAN)NAT2 has also been
shown to influence the incidence of sporadic and teratogen-
induced orofacial clefting [18]. Moreover, folate supplementation
during pregnancy seems to reduce the incidence of oral clefts in
newborns [19].
Like humans, mice have two functional NAT genes [20–22].
Historically, the characterisation of NAT polymorphisms in the
mouse preceded the discovery of polymorphism in (HUMAN)-
NAT1; the polymorphic murine NAT is therefore designated
(MOUSE)NAT2 by analogy with (HUMAN)NAT2 [23], despite
the fact that it shares the wide tissue distribution, pattern of
expression during embryonic development [24] particularly in
foetal neural tissues [25] and substrate specificity of (HUMAN)-
NAT1 [20].
Both biochemical and transgenic evidence suggest a link
between NAT and folate (Figure 1). In humans, intracellular
folate levels in erythrocytes appear to be inversely correlated with
cellular pABA N-acetylation activity [26], and folate and its
analogues have been identified as inhibitors of in vitro arylamine N-
acetylation measured with several sources of enzymes including
pure recombinant (HUMAN)NAT1 [14,26]. Furthermore, both
(HUMAN)NAT1 and (MOUSE)NAT2 are able to acetylate the
folate catabolite para-aminobenzoyl-1-glutamate (pABAglu) [20] as
well as pABA (Figure 1).
Over the last decade or so, the development of mouse models
has greatly enhanced our understanding of the biological role of
(MOUSE)NAT2 (and, by analogy, (HUMAN)NAT1). Observa-
tions in knockout mouse lines have suggested that (HUMAN)-
NAT1 and its homologue (MOUSE)NAT2 may play a role in
folate catabolism [27]. Targeted insertion of a LacZ transgene
into the (MOUSE)NAT2 locus provided a functional knockout
which also acts as a reporter model for expression of the
(MOUSE)Nat2 gene [28]. The resulting NAT2 null mice appear
phenotypically normal, but their livers, kidneys and urine
contain no detectable N-acetyl-pABAglu and they exhibit
biochemical abnormalities in 5-methyl tetrahydrofolate and S-
adenosylmethionine homeostasis [29,30]. Whole-mount histo-
chemical staining indicates that the transgene is expressed in the
closing neural tube of the developing embryo in this line. The
closure process occurs normally in the majority of transgenic
embryos, but an increased incidence of posterior NTDs and
occasional ocular defects is detected when there is a genetic
imbalance between the parents [29,31].
Mice engineered with constructs designed to drive overexpres-
sion of (HUMAN)NAT1 exhibit poor survival and the progeny of
the few surviving founders only exhibit small increases in hepatic
pABA acetylation [32,33], suggesting that (HUMAN)NAT1
overexpression during development could be harmful, possibly
due to disruption of folate homeostasis. Moreover, the overex-
pression of (HUMAN)NAT1 in mice provokes NTDs usually
associated with folate deficiency [32,34,35] and has complex
effects on the incidence and severity of orofacial clefting [33].
Folate-dependent methylation appears to play a role in the
epigenetic regulation of (MOUSE)NAT2 expression: specifically,
tissue-specific CpG methylation of the promoter region increases
in a strongly cell cycle-associated fashion after functional deletion
of the gene or following dietary folate supplements [36], consistent
with the aberrant expression of (HUMAN)NAT1 in certain
developmental defects and cancers. In humans, promoter
hypomethylation associated with increased (HUMAN)NAT1
mRNA expression has been demonstrated in infiltrating ductal
carcinomas of the breast [37].
The overexpression of (HUMAN)NAT1 may be of pathological
significance. Proteomic analysis has identified (HUMAN)NAT1 as
one of the predominant proteins overexpressed in invasive ductal
and lobular breast cancers; moreover, cellular proliferation and
the acquisition of etoposide resistance was observed when
(HUMAN)NAT1 overexpression was induced in non-cancerous
human breast cell lines [38]. In addition, transcriptional profiling
has identified (HUMAN)NAT1 as a potential prognostic biomark-
er in male breast cancer [39].
Studies using human breast tumour-derived cell lines have
indicated a 50-fold range of (HUMAN)NAT1 activities among
estrogen-receptor (ER)-positive cell lines, the highest activity being
observed in the ZR-75-1 line [3,40]. These observations led
various investigators to evaluate small molecule libraries with a
view to identifying (HUMAN)NAT1 inhibitors with chemother-
apeutic potential [1,41–45]. Particular attention has been paid to
the small molecule naphthoquinone 1 because of its striking
selectivity for (HUMAN)NAT1/(MOUSE)NAT2 (Figure 1A) and
its diagnostic/prognostic potential in ER-positive breast tumours
[44,45].
The aim of the present study was to determine whether
(HUMAN)NAT1 and its murine homologue can catalyse the
direct hydrolysis of acetyl Coenzyme A in the presence of folate.
We characterised enzyme selectivity using a broad panel of
eukaryotic and prokaryotic NAT enzymes, and describe here
experiments demonstrating that (HUMAN)NAT1 and its homo-
logue (MOUSE)NAT2, but not prokaryotic NATs, can catalyse
this reaction even in the absence of any arylamine substrate. We
also investigated the catalytic mechanism and final products of the
reaction. Folate was not acetylated during the reaction; instead,
the acetate released from AcCoA entered the bulk solvent. We
propose that folate is a cofactor for the hydrolysis of AcCoA by
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(HUMAN)NAT1 and its mouse equivalent (MOUSE)NAT2 and
suggest this reaction as an endogenous function of this widespread
enzyme, differing from that of (HUMAN)NAT2, where the
presence of an added arylamine is essential to permit appreciable
rates of AcCoA hydrolysis to occur.
Materials and Methods
Chemicals
All chemicals were purchased from Sigma-Aldrich unless
otherwise stated. Molecular biology reagents were obtained from
Promega (Southampton, UK). Competent cells were purchased
from Promega and Invitrogen (Carlsbad, USA).
Expression of Pure Recombinant NAT Enzymes
Recombinant NAT enzymes were prepared as described
previously [5,20,46–53]. Human ((HUMAN)NAT1), murine
((MOUSE)NAT1 and (MOUSE)NAT2) and prokaryotic NATS
(from Salmonella typhimurium, Mycobacterium marinum, Mycobacterium
smegmatis, Pseudomonas aeruginosa and Mycobacterium tuberculosis
((SALTY)NAT, (MYCMR)NAT, (MYCSM)NAT, (PSEAE)NAT)
and (MYCTU)NAT)) were evaluated.
Detection of Catalytic AcCoA Hydrolysis by HPLC Analysis
The activity of pure recombinant (HUMAN)NAT1 protein was
measured using reverse-phase HPLC as previously described by
Grant et al. [54]. Enzyme samples were first incubated with folate
(500 mM, final 5% DMSO (v/v)) in assay buffer (25 mM Tris-
HCl, pH 7.5) at 37uC for 5 min. The reaction was started by
adding AcCoA to a final concentration of 400 mM (final volume
100 mL) and allowed to proceed at 37uC for various periods of
time (up to 60 min). The reaction was quenched by adding
100 mL of ice-cold aqueous perchlorate (15% w/v), precipitated
proteins were removed by centrifugation for 5 min at 12,000 g and
20 mL of the supernatant was injected onto a C18 reverse-phase
HPLC column.
Determination of NAT Activity using Colorimetric Assays
Two methods which have previously been demonstrated to give
equivalent results [55] were used to determine NAT activity; one
quantified the direct disappearance of the arylamine over time, the
other estimated the formation of the Coenzyme A (CoA) product.
Assays were conducted in triplicate and the rates and kinetic
parameters quoted represent the mean of three independent
measurements 6 standard deviation unless otherwise stated. In
some experiments, the ability of n-propionyl CoA to replace
AcCoA was investigated using the same methods.
Figure 1. Potential role of (HUMAN)NAT1 and (MOUSE)NAT2 in folate degradation. One endogenous role of (HUMAN)NAT1 and
(MOUSE)NAT2 appears to be related to the breakdown of folate through the acetylation of the folate catabolites pABAglu and pABA. Small molecule
inhibitors such as naphthoquinone 1 (shown in red) are valuable tools which can be used to enhance our understanding of this proposed role.
doi:10.1371/journal.pone.0096370.g001
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Determination of NAT activity in terms of substrate
acetylation. A modification of the method of Andres et al. [56]
was used to determine the rates of enzymatic reactions with
arylamine substrates. Samples of (MOUSE)NAT2 (5 ng), with
pABA as the arylamine substrate (150 mM), were pre-incubated at
37uC in assay buffer (20 mM Tris-HCl, pH 8.0 containing 1 mM
DTT) for 5 min in a 96-well plate (Corning). The reaction was
initiated by adding pre-warmed AcCoA to a final concentration of
400 mM (final volume 45 mL), allowed to proceed for the
appropriate time at 37uC and quenched by adding an equal
volume of 20% (w/v) aqueous trichloroacetic acid solution at 0uC.
The colorimetric reagent para-dimethylaminobenzaldehyde
(DMAB) (5% (w/v) in 90% aqueous CH3CN solution, 150 mL)
was added and after 15 min incubation at room temperature the
absorbance was measured at 450 nm in a 96-well plate reader
(Tecan Sunrise). The remaining arylamine concentration was
calculated by reference to a standard curve. Folate could be
detected using a similar method because its pteridine moiety
possesses a primary amino group which can react with DMAB to
form a coloured product detectable at 450 nm. The reactivity of
folic acid with DMAB is lower than that of pABA but sufficient
concentration-dependent linearity was observed to permit this
reaction to be used to detect free folate and evaluate the potential
for folate acetylation.
Determination of NAT activity in terms of AcCoA
hydrolysis. The formation of CoA was determined spectro-
photometrically using the colorimetric agent 5,59-dithio-bis(2-
nitrobenzoic acid) (Ellman’s reagent, DTNB) as described
previously [55], with some minor modifications. This method is
applicable to a wide range of arylhydrazines and arylhydroxyla-
mines as well as arylamines; for the purposes of this study, the
appropriate substrate was chosen according to Westwood et al.
[57] depending upon the enzyme under investigation. Following
preincubation of a reaction mixture containing the relevant
enzyme with its arylamine substrate in assay buffer (20 mM Tris-
HCl, pH 8.0) for 5 min at 37uC, pre-warmed AcCoA in assay
buffer was added to 400 mM final concentration, starting the
reaction (final volume 100 mL), which was allowed to proceed at
37uC. After the appropriate incubation time, simultaneous
quenching and colour development was achieved by addition of
DTNB (5 mM in 100 mM Tris-HCl, 6.4 M guanidine.HCl,
pH 7.3; 25 mL). The absorbance was read immediately at 405 nm
and the rate of reaction was determined by reference to a standard
curve. The same method was used to examine the hydrolysis of n-
propionyl CoA.
Use of NMR to Determine Folate-dependent AcCoA
Hydrolysis by (MOUSE)NAT2
Prior to the commencement of enzymatic experiments, 1H-
NMR spectra of all the reagents and potential products of the
assay were recorded using a Bruker Avance AVIII 700 spectrom-
eter at the following concentrations: AcCoA (400 mM), folate
(150 mM), CoA (400 mM), and acetic acid (AcOH) (400 mM), all in
phosphate-buffered saline solution in D2O (PBS-D2O; pD 7.4)
(Figures S1, S2, S3). Each peak was assigned to the corresponding
proton consistent with previous full assignments [58–60]. Most of
the chemical shifts of AcCoA and CoA protons were similar, but
the chemical shifts of protons 60 and 90 differed and were chosen
as markers of these two molecules in a real-time 1H-NMR assay.
The concentration of folate used in the assay (150 mM) permitted
recognition of all spectral bands and the possible AcOH product
could be identified from a singlet at 1.97 ppm. The characteristic
resonances corresponding to all reagents and products were found
to be distinguishable in the spectra of the assay mixture at the
concentrations stated; the range from 3.2 to 1.6 ppm was chosen
as the most adequate region to follow the enzymatic AcCoA
hydrolysis by (MOUSE)NAT2 in the presence of folate (Figure
S4).
For the determination of folate-dependent AcCoA hydrolysis
activity, the reaction mixture comprised purified recombinant
(MOUSE)NAT2 (25 mg), folate (150 mM) and AcCoA (400 mM) in
PBS-D2O at 37uC. Following the collection of basal data the
reaction was initiated by adding AcCoA to a final concentration of
400 mM and monitored by real-time 1H-NMR using a Bruker
Avance AVII 500 MHz spectrometer. The field was locked by
external referencing to the relevant deuteron resonance (D2O).
The integration values were corrected appropriately and refer-
enced to a common internal standard (DMSO; 5% (v/v)).
Structural Docking Simulations
All images showing protein structures were generated using
PyMOL software [61]. The ground state conformation of folate
was predicted using the molecular editor Avogadro. Analysis of the
possible interactions between folate and the active site of
(HUMAN)NAT1 (pdb: 2PQT) [6] were performed using the
licensed software GOLD [62]. A docking site was defined as a
region of 10 A˚ within the active pocket of the enzyme and the
generated solutions were ranked by their GOLD Score Fitness
functions.
Modelling was also used to compare the shape and electron
density of folate with that of CoA. The conformation of CoA used
in these studies was that extracted from the co-crystal structure of
CoA with (HUMAN)NAT2 [6]. Modelling was carried out using
the licensed software FORGE (Cresset Group, Litlington,
Cambridgeshire, UK). CoA from its co-crystal structure with
(HUMAN)NAT2 was used as the reference molecule, and folate
was used as the test ligand. Modelling was carried out comparing
the two molecules both in free space and subsequently using
(HUMAN)NAT2 as an excluded volume.
Results and Discussion
(HUMAN)NAT1 and (MOUSE)NAT2, but not other NATs,
can act as Folate-dependent Acetyl CoA Hydrolases
A truncated form of (HUMAN)NAT1 with a shortened C-
terminus is known to be able to catalyse the hydrolysis of AcCoA
without transfer of the acetyl moiety to the arylamine substrate [8].
Such hydrolysis has also been demonstrated with truncated forms
of the NAT enzyme from S. typhimurium [63], but has not, to date,
been observed in routine enzymatic assays using full length
mammalian NAT isoforms.
We initially used HPLC analysis to determine whether pure
recombinant (HUMAN)NAT1 could act as an AcCoA hydrolase
in the presence of folate alone and found that, over a 30 minute
reaction period, the peak corresponding to AcCoA gradually
reduced in area while the area of the CoA peak increased
(Figure 2). The disappearance of the peak corresponding to
AcCoA and appearance of the CoA peak was clear from the
sequential HPLC traces; however, no change in the folate peak
was observed, indicating that the role of folate in this reaction was
not as a substrate. This behaviour was characteristic of
(HUMAN)NAT1 as opposed to (HUMAN)NAT2, and was also
observed in the presence of other folate analogues or moieties,
such as methotrexate, pterin, and pteroic acid, but with lower
efficiency (results not shown).
Following the discovery that (HUMAN)NAT1 can hydrolyse
AcCoA in the presence of folate, the ability of its homologue,
(MOUSE)NAT2, to act as a folate-dependent AcCoA hydrolase
From Arylamine N-Acetyltransferase to Acetyl CoA Hydrolase
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was also investigated. Single time point analytical assays were
performed with (MOUSE)NAT2 in order to evaluate the possible
fate of the reaction participants. In preliminary experiments to
determine whether (MOUSE)NAT2 can hydrolyse AcCoA in the
presence of folate, reactions were carried out in the presence of:
pABA and AcCoA; pABA, folate (in equimolar concentrations)
and AcCoA; or folate and AcCoA in the absence of pABA
(Figure 3A). The results obtained confirmed the ability of
(MOUSE)NAT2 to acetylate the arylamine pABA (150 mM) in
the presence of AcCoA and demonstrated that the addition of
150 mM folate to the reaction did not affect this activity, whether
measured in terms of substrate acetylation or release of CoA. The
third set of conditions demonstrated that (MOUSE)NAT2 could
catalyse the time-dependent generation of CoA from AcCoA in
the presence of folate but that no acetylation of folate occurred, at
least under the single time-point conditions used. These results
suggest a possible role of folate as a cofactor for AcCoA hydrolysis
by both (HUMAN)NAT1 and (MOUSE)NAT2, rather than an
acetylation substrate. The ability of (MOUSE)NAT2, but not
(MOUSE)NAT1, to hydrolyse AcCoA in the presence of folate
corresponds with the ability of (HUMAN)NAT1 to act as a folate-
dependent AcCoA hydrolase, in contrast with (HUMAN)NAT2.
The time course of the AcCoA hydrolysis reaction catalysed by
(MOUSE)NAT2 in the presence of folate indicated that CoA
release approximated to linearity over 25 minutes (Figure 3B). No
hydrolysis of AcCoA was detected in the absence of (MOUSE)-
NAT2, confirming that hydrolysis of AcCoA in the presence of
folate was enzyme-dependent under the conditions used, nor was
AcCoA hydrolysis observed with (MOUSE)NAT2 alone, consis-
tent with conventional negative controls used in N-acetylation
assays with DTNB as a colorimetric quenching agent [55].
The AcCoA hydrolysing capacity of a range of other murine
and prokaryotic NATs was evaluated by means of similar
enzymatic assays performed in the presence of: 5-aminosalicylic
acid (5AS; 150 mM) as the arylamine substrate; both 5AS and
folate (each at 150 mM); or folate (150 mM) alone (Figure 3C). No
inhibition of 5AS acetylation activity was observed for any NAT
isoform in the presence of folate. The only isoform capable of
hydrolysing AcCoA in the presence of folate alone without an
acceptor arylamine substrate being added to the reaction mixture
was (MOUSE)NAT2. The rate of this reaction was estimated to be
360 mM.sec21.mg21. Another acyl donor substrate of (MOUSE)-
NAT2, n-propionyl CoA, was hydrolysed by the enzyme in the
presence of folate with a slightly lower activity
(290 mM.sec21.mg21) compared to AcCoA.
In order to estimate the folate concentration dependence of
AcCoA hydrolysis by (HUMAN)NAT1 and (MOUSE)NAT2,
increasing concentrations of folate were tested with each enzyme.
The hydrolytic activities measured were consistent with Michaelis-
Menten kinetics. Apparent dissociation constants for folate
(assumed to be acting as a cofactor) were estimated to be 75 mM
for (HUMAN)NAT1 and 71 mM for (MOUSE)NAT2. The
corresponding Vmax values were 583 mM.sec21.mg21 and
613 mM.sec21.mg21, respectively (Figure 3D).
In order to investigate whether the enzyme selectivity of folate-
dependent AcCoA hydrolysis is related to specific interactions
between the AcCoA substrate and the NAT enzyme, the structures
of several CoA-complexed NAT enzymes were compared. This
comparison indicated that the binding site for CoA (analogous to
AcCoA) involves the C-terminus but that the AcCoA binding site
differs from one NAT enzyme to another. In addition, the
existence of a loop between domains two and three appears to be
of great importance with regard to CoA binding specificity [2]:
shortening the third domain of (SALTY)NAT, either completely
or partially, leads to increased AcCoA hydrolysis and inability to
acetylate arylamines following formation of the acetyl-enzyme
intermediate [63]. In previous studies, a truncated version of
(HUMAN)NAT1 comprising only the first 204 residues was found
to hydrolyse AcCoA without concomitant acetylation of the
arylamine substrate [8]. Furthermore, Wang et al. [64] demon-
strated that the acetylated derivative of Syrian hamster NAT Type
2 could be hydrolysed in the presence of arylamines whose weak
nucleophilicity delays attack on the acetyl-Cys68 thioester bond.
In the absence of an arylamine substrate, hydrolysis of the rapidly
formed acetylated intermediate was only detected (at a velocity of
31–67 nM/sec) when high concentrations (4–8 mM) of enzyme
were used [65]. Moreover, under these conditions the half-life of
the acetylated enzyme intermediate was around 1 min, confirming
that the acetyl-enzyme intermediate was stable and suggesting that
spontaneous deacetylation was rate-limiting [65,66]. Enzyme
concentrations in the (MOUSE)NAT2 reactions presented in this
study were always #3 nM and negative control assays confirmed
that the production of free CoA by (MOUSE)NAT2 as a side
product of the reaction without the need of folate was close to or
below the limit of detection.
It is interesting that the exclusive function of both (HUMAN)-
NAT1 and (MOUSE)NAT2, which have identical C-termini, with
respect to AcCoA hydrolysis in the presence of folate corresponds
with the ability of these, but not other NAT isoforms, to acetylate
the bulkier arylamine pABAglu [20]. In the human isoforms, this is
thought to be a consequence of the unique presence of three key
residues which have bulky side chains (Phe125, Arg127 and
Tyr129) in the active site of (HUMAN)NAT1 compared with that
of (HUMAN)NAT2, which has serines at these positions [6],
making the substrate binding pocket of (HUMAN)NAT1 smaller
than that of (HUMAN)NAT2 and conferring this substrate
selectivity on (HUMAN)NAT1 compared with (HUMAN)NAT2.
Fate of the Acetyl Group Removed during NAT-mediated
AcCoA Hydrolysis
The finding that (HUMAN)NAT1 and (MOUSE)NAT2 could
hydrolyse AcCoA in the presence of folate but without an
Figure 2. (HUMAN)NAT1 hydrolyses AcCoA in the presence of
folate. The time course of AcCoA hydrolysis by (HUMAN)NAT1 in the
presence of folate was monitored. The reaction mixture was prepared
and incubated as described. Aliquots were taken every 2 minutes over a
30 minute time course and analysed by HPLC.
doi:10.1371/journal.pone.0096370.g002
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arylamine substrate raised the question of whether the acetyl
group is released directly into the bulk solvent (Figure 4, Pathway
(a)) or forms an unstable N-acetylfolate intermediate which
immediately decomposes, releasing free AcOH (Figure 4, Pathway
(b)).
Preliminary HPLC studies did not reveal any N-acetylated
folate species after AcCoA hydrolysis by (HUMAN)NAT1, nor
was AcOH detectable using this analytical technique; however, the
biochemical techniques used with (MOUSE)NAT2 were also
unable to provide information about the intermediate steps of the
catalytic mechanism. In order to resolve this issue, 1H-NMR
analysis was performed; (MOUSE)NAT2 was used in this
experiment because sufficiently large amounts of pure recombi-
nant protein (25 mg) were available to permit 1H-NMR analysis.
This allowed chemical modifications occurring during the catalytic
reaction to be analysed in real time, revealing that the
disappearance of acetyl CH3 from AcCoA (at 2.41 ppm) occurred
concomitantly with the appearance of a CH3 peak (at 1.97 ppm)
corresponding to that of free AcOH (Figure 5A). This was
consistent with the hypothesis that (MOUSE)NAT2 could catalyse
direct hydrolysis of AcCoA in the presence of folate, and that the
acetyl group of AcCoA was transferred to the bulk solvent as
AcOH. In contrast, no change in the chemical shifts of folate
protons was observed, suggesting that the chemical structure of
folate was not modified during the reaction; formation of an N-
acetylated intermediate of folate was therefore considered unlikely.
However, the formation of a transient N-acetylfolate intermediate
could not be excluded at this stage because of the possibility that it
could be hydrolysed in D2O too rapidly to be detected on the
NMR timescale.
In order to visualise the kinetics of folate-dependent AcCoA
hydrolysis by (MOUSE)NAT2, reaction progress curves were
drawn using the integration values of characteristic resonances
arising from AcCoA, CoA and AcOH over time in relation to
those of DMSO (5% (v/v)) as an internal standard. The peaks
corresponding to the acetyl CH3 groups of AcCoA and AcOH,
and the methylene groups in the a position relative to sulfur in
both AcCoA and CoA (numbered as 60 and 90 in Figures S2–S3),
were also taken into account. The resulting curves indicated non-
linear progression of the reaction, both in terms of loss of starting
reagent and formation of products, consistent with Michaelis-
Menten kinetics. The disappearance of the initial AcCoA was
apparently complete after ,23 min and the formation of both
products reached a maximum after the same period of time. When
all the integrations were converted into concentration values and
Figure 3. AcCoA hydrolysis by (MOUSE)NAT2 in the presence of folate. (A) Specific pABA (150 mM) acetylation activity by (MOUSE)NAT2
(5 ng) was followed in the absence (grey columns) or in the presence (white columns) of an equimolar concentration of folate. The concentration of
AcCoA was 400 mM in all assays. Specific AcCoA (400 mM) hydrolysis activity by (MOUSE)NAT2 (5 ng) was also followed in the presence of folate
(150 mM), but in the absence of an arylamine substrate (black columns). For each set of reagents, both primary amine acetylation and AcCoA
hydrolysis methods were used in parallel, yielding equivalent results. No acetylation of folate was detected in a corresponding acetylation assay. (B)
Time course of assay containing AcCoA (400 mM) and folate (150 mM), with 5 ng (MOUSE)NAT2 (squares); negative control: assay containing AcCoA
(400 mM) and folate (150 mM) only, without (MOUSE)NAT2 (diamonds). (C) Activity of mammalian and bacterial NATs as AcCoA hydrolases in the
presence of folate. Different NAT enzymes were tested in AcCoA hydrolysis assays in the presence of either the arylamine substrate 5AS (150 mM, grey
columns), both 5AS and folate (each at 150 mM, white columns) or folate alone (150 mM, black columns). (D) Initial velocities of AcCoA hydrolysis by
(HUMAN)NAT1 (triangles) and (MOUSE)NAT2 (circles) in the presence of different concentrations of folate. A Michaelis-Menten curve was fitted using
the formula: y = (Vmax6[folate])/(Km+[folate]).
doi:10.1371/journal.pone.0096370.g003
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plotted against time (Figure 5B), the initial reaction velocity was
calculated to be 21.662.1 mM.min21.
One possibility is that the primary amine moiety of folate is
initially acetylated to form an N-acetylfolate intermediate which is
subsequently hydrolysed; however, we did not detect such an
intermediate by any method used, including 1H-NMR. This may
be because no such intermediate exists; alternatively, if it does, it
may be turned over too rapidly for detection on the NMR
timescale and/or may never accumulate to a high enough level to
be detected by 1H-NMR. Given that the time for running a 1H-
NMR spectrum is around 4 sec, the initial rate of AcCoA
hydrolysis by (MOUSE)NAT2 suggests an estimate of ,1.4 mM
Figure 4. Two hypotheses for the mechanism of the AcCoA hydrolysis reaction catalysed by (MOUSE)NAT2 in the presence of
folate. Pathway (a) corresponds to hydrolysis of AcCoA with direct release of AcOH into the bulk solvent; Pathway (b) corresponds to the formation
of an unstable N-acetylfolate intermediate which immediately decomposes, releasing free AcOH.
doi:10.1371/journal.pone.0096370.g004
Figure 5. Real-time 1H-NMR analysis of (MOUSE)NAT2 activity as a folate-dependent AcCoA hydrolase performed in PBS-D2O. (A)
Purified recombinant (MOUSE)NAT2 (25 mg) was mixed with folate (150 mM) and AcCoA (400 mM) in buffer PBS-D2O (pD 7.4) and incubated at 37uC.
NMR data were collected before adding the enzyme (t = 0 min), and subsequently 5 min after enzyme addition. A selected region of the spectra (3.2
to 1.6 ppm) is shown, the signals being labelled as follows: folate (f), AcCoA (A), CoA (C), AcOH (a). (B) Enzymatic reaction progress curves of folate-
dependent AcCoA hydrolytic activity by (MOUSE)NAT2. Folate-dependent AcCoA hydrolysis by (MOUSE)NAT2 was monitored by following the
characteristic peaks of both reagent and products versus d6-DMSO as an internal standard with appropriate correction. Diamonds: AcCoA; Squares:
CoA; Triangles: AcOH.
doi:10.1371/journal.pone.0096370.g005
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for the concentration of the possible N-acetylfolate intermediate,
corresponding to ,1% of the initial amount of folate. This lies at
the very limit of detection by 1H-NMR and is certainly beyond the
limit of quantification by this method using standard techniques
[67]. These data therefore confirm that CoA and AcOH were
produced during (MOUSE)NAT2-mediated catalysis in the
presence of folate; however, it was not possible to determine
whether the reaction proceeded via direct hydrolysis of the AcCoA
with release of the acetyl group as free AcOH to the bulk solvent
or whether a transient intermediate was formed. Since the primary
amine of folic acid would be predicted to be less nucleophilic than
the primary amine of pABA, due to enhanced resonance
stabilisation of the nitrogen lone pair by the pterdine moiety,
folate is less likely to act as a nucleophile in the hydrolysis of acetyl-
Cys68 than pABA. Taking all this evidence together, therefore, we
consider that (MOUSE)NAT2, and by analogy (HUMAN)NAT1,
are likely to act as AcCoA hydrolases in the presence of folate
without forming an N-acetylated folate intermediate.
Inhibition of AcCoA Hydrolysis by a Selective
Naphthoquinone Inhibitor of (HUMAN)NAT1 and
(MOUSE)NAT2
In order to characterise the folate-dependent hydrolysis of
AcCoA further, we made use of a small molecule inhibitor (for
background information on small molecule inhibitors of NATs, see
[2]). Naphthoquinone 1 (Figure 6A) is a selective competitive
inhibitor of N-acetylation by (HUMAN)NAT1 and (MOUSE)-
NAT2 [44], and Scatchard analysis indicates that it binds to a
single site, specifically the active site, on (MOUSE)NAT2. In
addition, 1 shows the remarkable quality of changing colour from
red to blue on binding specifically to (HUMAN)NAT1 or
(MOUSE)NAT2, whereas it does not change colour on binding
to other isoforms, in particular (HUMAN)NAT2 [45].
The availability of large amounts of stable pure recombinant
(MOUSE)NAT2 allowed us to investigate the ability of naphtho-
quinone 1 to inhibit (MOUSE)NAT2-dependent AcCoA hydro-
lysis in three assay formats: arylamine N-acetylation in the absence
of folate, arylamine N-acetylation in the presence of folate, and the
folate-dependent AcCoA hydrolysis reaction (Figure 6B). As
demonstrated previously, naphthoquinone 1 is a potent inhibitor
of (MOUSE)NAT2 in the arylamine N-acetylation reaction;
however, the extent of inhibition was reduced by at least 20% in
the presence of added folate. In contrast, folate-dependent AcCoA
hydrolysis by (MOUSE)NAT2 was totally inhibited by naphtho-
quinone 1.
In order to verify that inhibition of folate-dependent AcCoA
hydrolysis by naphthoquinone 1 was not an artefact of the
enzymatic assay, its concentration dependence was characterised
(Figure 6C). This analysis indicated an IC50 of 0.14 mM (p,0.01).
This was roughly seven-fold lower than the IC50 of naphthoqui-
none 1 for arylamine N-acetylation (0.99 mM) [44].
In silico Docking of Folate within the Active Site of
(HUMAN)NAT1
The mechanism of AcCoA hydrolytic catalysis depends both on
the binding site and the sequence in which AcCoA and folate bind
to the enzyme. Folate-dependent AcCoA hydrolysis corresponds
to the first step of the conventional ping-pong bi-bi mechanism of
NAT catalysis in the presence of an arylamine substrate [2].
However, in an arylamine N-acetylation reaction the aromatic
primary amine is subsequently believed to attack the thioester
functional group of the acetyl-Cys68 intermediate, resulting in
transfer of the N-acetyl group to the aromatic amine [64], whereas
the proposed second step in an AcCoA hydrolysis reaction by
(MOUSE)NAT2 in the presence of folate is deacetylation of the
acetyl-Cys68 by a molecule of water to form AcOH.
Figure 6. Inhibition of (MOUSE)NAT2-dependent AcCoA hydrolysis by the small molecule inhibitor naphthoquinone 1. (A) Structure
of naphthoquinone 1, a selective inhibitor of (HUMAN)NAT1. (B) Screening of different enzymatic assays with (MOUSE)NAT2 in the presence of
naphthoquinone 1. AcCoA hydrolysis assays were carried out in order to monitor the inhibitory potency of naphthoquinone 1 at 10 mM. AcCoA was
present at 400 mM in all assays. Specific pABA (150 mM) acetylation activities by (MOUSE)NAT2 (5 ng) were performed in the absence (grey columns)
or presence (white columns) of an equimolar concentration of folate. Specific AcCoA hydrolysis activity was also detected in the presence of folate
(150 mM) in a DTNB assay without an arylamine substrate (black columns). The percentage inhibition was calculated in terms of the reduction in
(MOUSE)NAT2 specific activity measured against a control in which DMSO (5% (v/v)) alone was added to the assay. (C) Naphthoquinone 1 as an
inhibitor of the folate-dependent AcCoA hydrolytic activity of (MOUSE)NAT2. AcCoA hydrolysis assays were performed using (MOUSE)NAT2 (510 ng)
and AcCoA (400 mM) in the presence of folate (150 mM) and serial dilutions of naphthoquinone 1. Data points represent the mean 6 standard
deviation of triplicate assays. Percentage inhibition was determined as the ratio of specific activity with the inhibitor related to specific activity
without inhibitor (100%); 100% activity was 198 mM.sec21.mg21. The regression equation used was: y = 100/[1+10‘(x-log(IC50)].
doi:10.1371/journal.pone.0096370.g006
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This hypothetical mechanism requires a water molecule to gain
access to the active site acetyl-Cys68 in order to release the acetyl
group and contrasts with the situation pertaining in the case of the
arylamine N-acetylation reaction in which, following the acetyla-
tion of the catalytic cysteine, only highly hydrophobic molecules
such as arylamines and arylhydrazines can access the active site
pouch [6,57,68].
The observation that no appreciable AcCoA hydrolysis occurs
in control reactions with (MOUSE)NAT2 in the absence of an
arylamine substrate (or folate) is consistent with this hypothesis
[55]. Conversely, the observed hydrolysis of acetyl-Cys68 in the
presence of folate, despite the hydrophobicity of the active site
pocket, suggests that folate may modify the hydrophobicity of the
acetylated enzyme’s active site, thereby allowing water to enter the
active site pocket and cleave acetyl-Cys68, possibly as a
consequence of altered folding induced by the binding of folate.
We undertook modelling studies in an effort to predict the
nature of the interactions between (HUMAN)NAT1 and folate in
the case that it binds to the catalytic active site, which is likely
because the known (HUMAN)NAT1 specific substrates, pABAglu
and pABA, are chemical moieties of folate (Figure 1A). Modelling
using GOLD software suggests that the c-COOH of folate could
form hydrogen bonds with the backbone carbonyl of Ile106 and
the thiolate moiety of Cys68, and the a-COOH of folate could
interact with the backbone carbonyl of Gly124 and the imidazole
side chain of His107. Additionally, the pteridine carbonyl of folate
could potentially interact with the guanidine moiety of Arg127 and
the primary amine of folate with the backbone carbonyl of Lys188
and the hydroxyl groups of Thr96 and Tyr129 (Figure 7).
Comparing the conformation of CoA as it is bound to the active
site of (HUMAN)NAT2, using an available co-crystal structure
(pdb code:2PFR), against free folate suggests marked similarities
between the shape and electron density of the two species
(Figure 8A). Repeatable simulations show that regions of positive
charge, negative charge and neutral regions for the two ligands
align well in space. Furthermore, when (HUMAN)NAT2 was used
as an excluded volume in this modelling, the same conclusions
could also be reliably drawn (Figure 8B).
It should be noted that these FORGE experiments involved a
comparison between the conformation of CoA as bound to
(HUMAN)NAT2 and that of free folate; thus the simulations
pertain to free folate, not the predicted conformation of
hypothetical enzyme-bound conformations of folate. We used
(HUMAN)NAT2 as an excluded volume to ensure that folate and
CoA were excluded from the same space, permitting a reliable
comparison between the shapes of the two molecules. This does
not necessarily suggest that folate is binding to the active site of
(HUMAN)NAT2 in this way; interestingly, when folate is docked
into the active site of (HUMAN)NAT2 it does give a good
predicted fit, but this does not necessarily imply binding of folate to
(HUMAN)NAT2 and even if folate does bind to (HUMAN)-
NAT2, it may not induce the conformational changes required for
AcCoA hydrolysis.
It is not possible to state whether our prediction regarding the
orientation of folate within the active site of (HUMAN)NAT1 is an
accurate representation of the real-life situation since no structures
of (HUMAN)NAT1 or other NAT enzymes complexed with folate
are yet available. Docking studies based on the structure of an
acetylated form of (HUMAN)NAT1 would be particularly
informative in this context. Biochemical studies have yielded
discordant results concerning the mode of inhibition of eukaryotic
NATs by folate; however, the data presented in this paper suggest
a possible explanation in that folate-dependent inhibition of
arylamine N-acetylation may be due to concomitant depletion of
AcCoA via hydrolysis. In particular, some previous folate inhibitor
studies with human NATs [26], which measured NAT activity in
terms of arylamine N-acetylation, may not have taken into account
the possibility of direct hydrolysis of AcCoA.
A representative crystal structure of a folate-bound NAT
enzyme is required for a complete definition of the folate binding
site of (HUMAN)NAT1, which is needed before a hypothesis for
the catalytic mechanism for AcCoA hydrolysis by (HUMAN)-
Figure 7. In silico docking of folate into the active site of (HUMAN)NAT1. (A) Folic acid was docked into the active site of (HUMAN)NAT1
using the program GOLD [62]; the highest scoring solution is shown. The structure of (HUMAN)NAT1 (pdb code: 2PQT) [6] is shown in surface format
with the three domains labelled and coloured in different shades of blue. The domains are numbered from the amino terminus with Domain 3
corresponding to the C-terminus of the protein. Folic acid is labelled with carbon atoms in orange, nitrogen in blue, oxygen in red, and hydrogen in
white. (B) Maximised view of the (HUMAN)NAT1 active site with folic acid docked. The structure of (HUMAN)NAT1 is shown in cartoon format with the
three domains coloured as above. The side chains of the key residues involved in predicted folic acid binding within the catalytic pocket are labelled
with nitrogen in blue, oxygen in red, and sulfur in yellow. Folic acid is labelled with carbon atoms in orange, nitrogen in blue, oxygen in red, and
hydrogen in white.
doi:10.1371/journal.pone.0096370.g007
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NAT1 can be proposed. Although folate has a much higher
molecular weight (441.4 g.mol21) than selective (HUMAN)NAT1
arylamine substrates (,266.1 g.mol21 (pABAglu)) [6], our docking
simulations have highlighted potentially favourable complemen-
tary binding partners for the polar functional groups of folate in
the hydrophobic catalytic pocket of (HUMAN)NAT1 via hydrogen
bond interactions. It is possible that the accommodation of a large
molecule such as folate could induce further opening of the
(HUMAN)NAT1 active site and mediate the access of a molecule
of water to the cavity. Furthermore, modelling studies suggest that
the electron density distribution of folate may resemble that of
CoA, allowing it to bind to the active sites of human NATs in a
similar manner.
Crystallographic structural data are therefore required to clarify
the mechanism by which folate selectively facilitates AcCoA
hydrolysis by (HUMAN)NAT1. More broadly, our data raise
questions about the possible role that certain NAT enzymes could
play at the interface between AcCoA homeostasis and folate
metabolism.
Folic acid has been reported to act as a free radical scavenger
[69,70], and it is interesting to hypothesise a link between the
discovery that (HUMAN)NAT1 and (MOUSE)NAT2 can act as
AcCoA hydrolases in the presence of an appropriate amount of
folic acid and a potential role for (HUMAN)NAT1/(MOUSE)-
NAT2 and folate in the regulation of AcCoA/CoA homeostasis in
cells, especially under conditions of oxidative stress. The
availability of naphthoquinone 1 as a selective inhibitor of
folate-dependent AcCoA hydrolysis by (HUMAN)NAT1/(MOU-
SE)NAT2 adds to the available tool kit for the further investigation
of such possibilities. Indeed, (HUMAN)NAT1 has been postulated
as a novel biomarker in ER-positive breast cancer [40] and the
development of analogues of the naphthoquinone inhibitor 1 for
potential diagnostic and chemotherapeutic applications in breast
cancer treatment is a current area of interest [71].
Conclusions
The experiments described in this paper demonstrate that
(HUMAN)NAT1 and its homologue (MOUSE)NAT2 can catalyse
the direct hydrolysis of acetyl Coenzyme A in the presence of
folate. This folate-dependent activity is exclusive to these two
isoforms; no AcCoA hydrolysis was found when (HUMAN)NAT2,
(MOUSE)NAT1 or recombinant bacterial NATs were incubated
with folate. Proton NMR allowed chemical modifications occur-
ring during the catalytic reaction to be analysed in real time; the
disappearance of acetyl CH3 from AcCoA occurred concomitantly
with the appearance of a CH3 peak corresponding to that of free
AcOH, suggesting that folate is not acetylated during the reaction.
We propose that folate is a cofactor for this reaction and suggest it
as an endogenous function of this widespread enzyme. Further-
more, in silico docking of folate within the active site of
(HUMAN)NAT1 suggests that folate may bind at the enzyme’s
active site and facilitate AcCoA hydrolysis.
The evidence presented in this paper both adds to our growing
understanding of the endogenous roles of (HUMAN)NAT1 and
(MOUSE)NAT2 and expands the catalytic repertoire of these
enzymes, demonstrating that they are by no means just xenobiotic
metabolising enzymes but probably play an important role in
cellular metabolism. Our data highlight the important question of
whether, and how, the NAT enzymes play a role at the interface
between AcCoA homeostasis and folate metabolism [2]. Further-
more, the characterisation of naphthoquinone 1 as an inhibitor of
folate-dependent AcCoA hydrolysis reinforces the value of this
compound as a powerful chemical tool which is likely to open up a
range of future avenues of exploration via selective modulation of
(HUMAN)NAT1 and (MOUSE)NAT2 function, both for im-
proved understanding of the developmental role of these enzymes
and for better chemotherapeutic approaches to ER-positive breast
cancer.
Supporting Information
Figure S1 Structure and proton NMR spectra of folic
acid. 500 MHz 1H-NMR spectrum of 400 mM AcCoA in D2O,
pD 7.4, 25uC (room temperature). Fully resolved spectral
assignments were made on the basis of previous studies [72,73].
(TIF)
Figure S2 Structure and proton NMR spectra of AcCoA.
500 MHz 1H-NMR spectrum of 400 mM AcCoA in D2O, pD 7.4,
25uC (room temperature). Fully resolved spectral assignments were
Figure 8. Structural similarity between folate and AcCoA. (A) Predicted alignment between folic acid and CoA in free space using the software
program FORGE, based on the conformation of CoA as it is bound in the co-crystal structure with (HUMAN)NAT2 (pdb code: 2PFR). Folic acid is shown
in thick sticks, with carbons in grey, and CoA is shown in thin sticks, with carbon atoms in green. Nitrogen atoms are shown in blue, oxygens in red,
and hydrogens in white. Regions of negative charge are shown in cyan, regions of positive charge are shown in dark red, and lipophilic regions are
shown in yellow. Icosahedra represent the electronic fields of CoA and spheres represent those of folic acid. (B) Predicted alignment between folic
acid and CoA using (HUMAN)NAT2 as an excluded volume. Folic acid, CoA and their respective electron density distributions are represented as
above. The (HUMAN)NAT2 structure is represented in thin sticks with the carbon atoms in lilac.
doi:10.1371/journal.pone.0096370.g008
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made on the basis of previous studies [58,59]. The spectral bands
of proton 29, 39 and 49 were assumed to be hidden by the D2O
signal. Traces of Tris.HCl buffer from AcCoA stock solutions were
observed.
(TIF)
Figure S3 Structure and proton NMR spectra of CoA.
700 MHz spectrum of 400 mM CoA in D2O, pD 7.4, 25uC (room
temperature). Fully resolved spectral assignments were made on
the basis of previous studies [58–60].
(TIF)
Figure S4 NMR spectra of reagents and possible
products present in an AcCoA hydrolysis assay with
(MOUSE)NAT2. NMR spectra were recorded with a Bruker
AVC 500 spectrometer at 500 MHz or, for CoA, an AV700
spectrometer at 700 MHz at the optimal concentrations used in
the AcCoA enzymatic assay: 400 mM for AcOH, CoA, AcCoA,
and 150 mM for folate. The blue square highlights the range of
chemical shifts chosen to follow the enzymatic assay over time.
(TIF)
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